reviewJournal of Clinical OncologyJul 14, 2004Closed access

The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway

Brigham and Women's Hospital · Harvard University · +2 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Genetic alterations targeting the PTEN tumor suppressor gene are among the most frequently noted somatic mutations in human cancers. Such lesions have been noted in cancers of the prostate and endometrium and in glioblastoma multiforme, among many others. Moreover, germline mutation of PTEN leads to the development of the related hereditary cancer predisposition syndromes, Cowden disease, and Bannayan-Zonana syndrome, wherein breast and thyroid cancer incidence is elevated. The protein product, PTEN, is a lipid phosphatase, the enzymatic activity of which primarily serves to remove phosphate groups from key intracellular phosphoinositide signaling molecules. This activity normally serves to restrict growth and…

No related works found for this paper.